Skip to main content
Equibles

BCHMY · Bachem Holding AG

Track BCHMY — free

Use BCHMY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BCHMY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.69 -0.31 (-3.10%) At close · Nov 12
Rebalance outlook locked
Market Cap
$7.13B
Shares
749.36M
Volume · Nov 12 105 Avg daily vol (3M) 1922

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$9.69 Open$10.00 Day$9.69–10.00 52W close$5.97–10.99 Avg vol 30d2K Short int2K · 0.0% of shares · 1.0d Short vol5% DataMar 2023–Nov 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
1.2%
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+47.9%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.7 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg −1%
below
RSI (14) 48
neutral
MACD trend Negative
52-week position 74%
mid-range
Momentum
relative strength
Weak
1-month return +1%
trailing
6-month return −10%
trailing
YTD return +34%
this year
Relative strength −12%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow Distributing
1 of 1 funds reported for Sep 30 · net -90 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of shares out · ▼ -62.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Squeeze score 18
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −28%
past year
ATR 4.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
−1% Neutral
RSI (14)
48 Neutral
MACD trend
Negative Bearish
52-week position
74% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $10 › 200d $9 — 50d above 200d
Institutional flow Distributing
1 of 1 funds reported for Sep 30 · net -90 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of shares out · ▼ -62.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $6 Now $10 · 74% Range high $11
vs 200-day avg +8% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BCHMY
Bachem Holding AG
this stock
$7.13B +33.8% — — 0.0%
VRTX
Vertex Pharmaceuticals Inc
 $137.57B +19.7% +46.2% 34.9 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.40B +23.2% +20.8% 21.0 2.1%
MRNA
Moderna, Inc.
 $93.61B +684.5% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1
% held
0.0%
Reported
1 of 1
Top holder
RHUMBLINE ADVISERS
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
1.6K
Days to cover
1.0d
Change
-2.6K sh
View
Short Volume
Short vol %
5%
As of
Nov 11, 2026
Short Total
View
Fails to Deliver
FTD shares
3.8K
Value
$35.0K
As of
Jul 28, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Oct 5, 2026
Off-exch Lit
View
Earnings & Events
Investor Relations
Upcoming events
5
View

Performance

5D 20D 120D MTD YTD
BCHMY -4.1% +1.3% -10.3% -5.0% +33.8%
SPY +3.3% -1.9% +1.5% +0.2% +11.0%
vs SPY -7.4% +3.2% -11.8% -5.2% +22.8%

Capital returns

Latest dividend
$0.1153 / share · ex May 5, 2026
Raised 120.6%
Paid (TTM)
$0.1153 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1968378 CUSIP 05636G105 13F (30d) 1 filings 1 filers Visit website Investor relations